Previous Close | 2.0500 |
Open | 2.0800 |
Bid | 1.1300 x 1800 |
Ask | 2.0000 x 1200 |
Day's Range | 1.9300 - 2.1900 |
52 Week Range | 1.0500 - 5.9500 |
Volume | |
Avg. Volume | 39,522 |
Market Cap | 35.531M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.7320 |
Earnings Date | Nov 10, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 6.33 |
Subscribe to Yahoo Finance Plus to view Fair Value for DERM
SCOTTSDALE, Ariz., Jan. 20, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or the “Company”), a commercial-stage biopharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced that Ernest (Ernie) De Paolantonio has notified the Company that, effective January 27, 2023, he will step down as Chief Financial Officer of Journey Medical to pursue another
Topline data expected in the first half of 2023SCOTTSDALE, Ariz., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), a commercial-stage biopharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced that it has fully enrolled and randomized all of the patients in its Phase 3 clinical program to assess the safety, efficacy and tolerability of D
Journey Medical Corporation (NASDAQ: DERM) announced PK comparability data of DFD-29 and key updates on the progress of its pivotal, Phase 3 study of DFD-29 for papulopustular rosacea in collaboration with Dr. Reddy's Laboratories Ltd (NYSE: RDY). Papulopustular rosacea is associated with "whitehead" pustules, pus-filled blemishes, and red, swollen bumps. The PK study was designed as a comparative bioavailability study of DFD-29 (Minocycline Modified Release Capsules 40 mg) versus Solodyn (Minoc